Publication | Closed Access

Decreased serum amyloid β1–42 autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1–42 peptide

Neurodegenerative DiseasesAlzheimer's DiseaseAutoimmune DiseaseImmunologyBiomarkersProtein MisfoldingAutoantibodiesNeurologyNeuroscienceNeurodegenerationImmuno-precipitation AssayAging-associated DiseaseMedicine